Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Staphylococcus | 2 | 2019 | 77 | 0.89 | Why? |
| Babesiosis | 2 | 2017 | 22 | 0.88 | Why? |
| Babesia microti | 2 | 2017 | 9 | 0.75 | Why? |
| Mycobacterium Infections | 1 | 2017 | 72 | 0.69 | Why? |
| Tick-Borne Diseases | 1 | 2017 | 68 | 0.64 | Why? |
| Antiparasitic Agents | 1 | 2017 | 267 | 0.56 | Why? |
| Staphylococcal Infections | 2 | 2019 | 1099 | 0.47 | Why? |
| High-Throughput Screening Assays | 1 | 2020 | 1783 | 0.44 | Why? |
| Anaplasmosis | 2 | 2019 | 21 | 0.38 | Why? |
| Anaplasma phagocytophilum | 2 | 2019 | 34 | 0.38 | Why? |
| Bacterial Infections | 1 | 2021 | 2229 | 0.33 | Why? |
| Anti-Bacterial Agents | 8 | 2021 | 10083 | 0.28 | Why? |
| Erythrocyte Transfusion | 2 | 2019 | 386 | 0.28 | Why? |
| Coinfection | 2 | 2021 | 6820 | 0.26 | Why? |
| Streptococcal Infections | 2 | 2017 | 255 | 0.26 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.25 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.24 | Why? |
| Bacterial Physiological Phenomena | 1 | 2021 | 31 | 0.23 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.22 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.22 | Why? |
| Granulomatous Mastitis | 1 | 2018 | 8 | 0.19 | Why? |
| Lysostaphin | 1 | 2018 | 1 | 0.19 | Why? |
| Legionellosis | 1 | 2018 | 31 | 0.19 | Why? |
| Mycobacterium haemophilum | 1 | 2017 | 5 | 0.19 | Why? |
| Fracture Healing | 1 | 2018 | 37 | 0.18 | Why? |
| Atovaquone | 1 | 2017 | 19 | 0.18 | Why? |
| Urinary Tract | 1 | 2018 | 77 | 0.18 | Why? |
| Levofloxacin | 1 | 2018 | 115 | 0.18 | Why? |
| Blood Culture | 1 | 2020 | 308 | 0.17 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.17 | Why? |
| Streptococcus | 1 | 2017 | 76 | 0.17 | Why? |
| Antiprotozoal Agents | 1 | 2017 | 83 | 0.17 | Why? |
| Multiple Pulmonary Nodules | 1 | 2018 | 115 | 0.17 | Why? |
| Ixodes | 1 | 2017 | 58 | 0.17 | Why? |
| Diagnostic Tests, Routine | 2 | 2020 | 2643 | 0.17 | Why? |
| Academies and Institutes | 1 | 2020 | 539 | 0.16 | Why? |
| Aminopeptidases | 1 | 2016 | 41 | 0.16 | Why? |
| Hydrogels | 1 | 2018 | 173 | 0.16 | Why? |
| Transfusion Reaction | 1 | 2019 | 245 | 0.16 | Why? |
| Streptococcus agalactiae | 1 | 2017 | 194 | 0.15 | Why? |
| New York | 2 | 2020 | 2488 | 0.15 | Why? |
| Cell-Free Nucleic Acids | 1 | 2018 | 271 | 0.14 | Why? |
| Urinary Bladder Neoplasms | 2 | 2018 | 614 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.14 | Why? |
| Neutropenia | 1 | 2018 | 388 | 0.14 | Why? |
| Hemolysis | 1 | 2017 | 283 | 0.14 | Why? |
| Rotavirus Vaccines | 1 | 2017 | 203 | 0.14 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.14 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.14 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 2426 | 0.14 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.14 | Why? |
| Acinetobacter baumannii | 1 | 2017 | 378 | 0.14 | Why? |
| Prosthesis-Related Infections | 1 | 2018 | 302 | 0.14 | Why? |
| Fatal Outcome | 3 | 2019 | 3438 | 0.13 | Why? |
| Thailand | 1 | 2017 | 1155 | 0.13 | Why? |
| Rotavirus Infections | 1 | 2017 | 355 | 0.12 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.12 | Why? |
| Pseudomonas aeruginosa | 1 | 2017 | 652 | 0.12 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.12 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.12 | Why? |
| Bacteremia | 2 | 2020 | 1372 | 0.12 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.11 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.11 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.10 | Why? |
| Bacteria | 1 | 2021 | 1897 | 0.10 | Why? |
| New York City | 5 | 2021 | 7432 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 877 | 0.10 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.10 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.10 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.09 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.09 | Why? |
| Exanthema | 1 | 2017 | 1097 | 0.09 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.08 | Why? |
| Humans | 31 | 2021 | 930598 | 0.08 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.08 | Why? |
| Biosensing Techniques | 1 | 2021 | 2116 | 0.08 | Why? |
| United States | 5 | 2021 | 46150 | 0.08 | Why? |
| Azithromycin | 2 | 2020 | 3943 | 0.08 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.08 | Why? |
| Female | 17 | 2021 | 380317 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Models, Biological | 1 | 2021 | 4907 | 0.06 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.06 | Why? |
| Male | 17 | 2021 | 367725 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Mice | 2 | 2018 | 21357 | 0.05 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.05 | Why? |
| Factor XI Deficiency | 1 | 2018 | 7 | 0.05 | Why? |
| Infant | 5 | 2020 | 30274 | 0.05 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.05 | Why? |
| Corynebacterium | 1 | 2018 | 47 | 0.05 | Why? |
| Sensitivity and Specificity | 4 | 2021 | 22971 | 0.05 | Why? |
| Sequence Analysis | 1 | 2020 | 496 | 0.05 | Why? |
| Histiocytes | 1 | 2018 | 97 | 0.05 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.05 | Why? |
| Streptogramins | 1 | 2017 | 2 | 0.05 | Why? |
| Polycyclic Compounds | 1 | 2017 | 5 | 0.05 | Why? |
| Legionella | 1 | 2018 | 91 | 0.04 | Why? |
| Erythromycin | 1 | 2017 | 17 | 0.04 | Why? |
| Lincosamides | 1 | 2017 | 23 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| Biological Assay | 1 | 2020 | 367 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.04 | Why? |
| Clindamycin | 1 | 2017 | 59 | 0.04 | Why? |
| Adult | 12 | 2021 | 244371 | 0.04 | Why? |
| Societies | 1 | 2017 | 95 | 0.04 | Why? |
| Perioperative Period | 1 | 2018 | 276 | 0.04 | Why? |
| Femoral Fractures | 1 | 2018 | 104 | 0.04 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Giant Cells | 1 | 2018 | 334 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.04 | Why? |
| Biocompatible Materials | 1 | 2018 | 214 | 0.04 | Why? |
| Diterpenes | 1 | 2017 | 157 | 0.04 | Why? |
| Prosthesis Design | 1 | 2018 | 594 | 0.04 | Why? |
| Allografts | 1 | 2018 | 761 | 0.04 | Why? |
| HLA Antigens | 1 | 2021 | 830 | 0.04 | Why? |
| Vagina | 1 | 2017 | 327 | 0.03 | Why? |
| Graft vs Host Disease | 1 | 2018 | 501 | 0.03 | Why? |
| Bacteriological Techniques | 1 | 2016 | 239 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Infant, Newborn | 3 | 2020 | 23105 | 0.03 | Why? |
| Animals | 3 | 2018 | 78931 | 0.03 | Why? |
| Drug Interactions | 1 | 2021 | 1653 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2020 | 1357 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.03 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.03 | Why? |
| Anemia | 1 | 2018 | 789 | 0.03 | Why? |
| Gastrointestinal Tract | 1 | 2018 | 1113 | 0.03 | Why? |
| Child | 4 | 2020 | 70012 | 0.03 | Why? |
| Equipment Design | 1 | 2021 | 3095 | 0.02 | Why? |
| Lung | 1 | 2018 | 31049 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
| Coronavirus | 1 | 2018 | 18339 | 0.02 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Pregnancy | 2 | 2017 | 23879 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.02 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.01 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
Westblade's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(243)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_